Protocol for Home-Based Solution for Remote Atrial Fibrillation Screening to Prevent Recurrence Stroke (HUA-TUO AF Trial): a randomised controlled trial. Issue 7 (15th July 2022)

• Record Type: Journal Article
• Authors: Wong, Chun Ka; Hai, Jo Jo; Lau, Yuk-Ming; Zhou, Mi; LUI, Hin-Wai; Lau, Kui Kai; Chan, Koon-Ho; Mok, Toi Meng; Liu, Yong; Feng, Yingqing; Tan, Ning; Tam, Weng-Chio; Tam, Kun-Chong; Feng, Xiuhua; Zuo, Ming-Liang; Yin, Li-Xue; Tan, Jing; Zhang, Wen-Jun; Jiang, Xiaofei; Huang, Xiaoyu; Ye, Jianfeng; Liang, Yan; Jiang, Wei; Lei, Zhen; Huang, Duo; Yue, Wen-Sheng; Tan, Guanming; Yan, Bryan P; Evora, Mario Alberto; Chen, Ji-yan; Siu, Chung-Wah;
• Is Part Of: BMJ open. Volume 12:Issue 7(2022)
• Publication Date: 2022-07-15
• Subjects: Telemedicine -- Adult cardiology -- Stroke; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2021-053466
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Current international guidelines recommend ECG monitoring after an ischaemic stroke to detect atrial fibrillation (AF) in order to prevent stroke recurrence. However, optimal strategies to detect AF and the downstream management to prevent stroke recurrence remain to be established. The objective of the study was to explore the use of long-term home-based ECG monitoring for AF detection and stroke prevention in patients with a history of stroke. Methods and analysis: This prospective, randomised, open-label trial with blinded endpoint adjudication aimed to evaluate the efficacy of long-term home-based ECG monitoring for AF detection and stroke prevention in a 24-month period. Patients aged >18 years with a history of ischaemic stroke will be stratified according to the time from the index ischaemic stroke: <1, 1–3 and >3 years and then randomised in 1:1 to (1) home-based AF screening and (2) control. The home-based AF screening system comprises (1) a handheld single-lead ECG recorder (Comfit Healthcare Devices, Hong Kong SAR, China) and (2) a patient-facing smartphone application specially designed for the study. Patients randomised to the home-based AF group will record a 30 s single-lead ECG using a specially designed handheld ECG device every morning or when symptomatic. All remotely obtained data will be automatically transmitted in real-time through the study smartphone application to a secured cloud hosting and analysed using an artificial intelligence-based diagnostic system. When a diagnosis of AF is made with the system, the patients will be called back for a formal cardiology consultation within 1 week. The primary endpoint is the time to first detection of AF at 24 months of follow-up. Secondary endpoints include recurrent stroke or transient ischaemic attack, initiation of long-term anticoagulation therapy, hospitalisation for heart failure, cardiovascular death and all-cause death. Ethics and dissemination: The study protocol has been approved by the institutional review board of The University of Hong Kong, and Hong Kong West Cluster, Hospital Authority, Hong Kong SAR, China. Results will be published in peer-reviewed journals. Trial registration number: NCT04523649 .